OKYO Pharma Limited

What they do

OKYO Pharma Ltd is a clinical-stage biopharmaceutical company with no marketed products, primarily engaged in research and development of therapeutic candidates. Its operations are centered on advancing drug candidates targeting inflammatory and neuropathic pain, with key collaborations and licenses with On Target Therapeutics, LLC and Tufts Medical Center, Inc. The company is headquartered in Guernsey with a principal executive office in London, UK, and its ordinary shares trade on the NASDAQ Capital Market.

Revenue drivers

• No commercial products — The company currently generates no revenue from product sales, as it is in the clinical development stage.
• Collaboration agreements — Revenue, if any, is expected to arise from collaboration and license agreements, such as those with On Target Therapeutics and Tufts Medical Center, though no such revenue is reported in the provided excerpts.

Recent performance

The filing is for the fiscal year ended March 31, 2026, and is an amendment to the original Form 20-F, filed to add the Clawback policy to the exhibit table. No financial results are disclosed in the provided excerpts, and the company states it has not modified or updated disclosures from the original filing. As of July 15, 2026, there were 52,479,527 ordinary shares outstanding. No revenue or net loss figures are cited in the excerpts.

Strategy

The company's stated direction is to advance its clinical development programs in pain indications, supported by its collaborations and license agreements. It maintains a pipeline of assets under license from On Target Therapeutics and Tufts Medical Center, indicating a reliance on external innovation. The company is a smaller reporting company and emerging growth company, suggesting a focus on efficient regulatory pathways. Key priorities include executing its development plans and managing its corporate structure, including its listing on NASDAQ and compliance with SEC requirements.

Risks

• Clinical-stage risk — No product has been approved or commercialized, so the company is dependent on successful completion of clinical trials and regulatory approval.
• Dependence on collaborations — The company relies on agreements with On Target Therapeutics and Tufts Medical Center for its core intellectual property and development capabilities.
• Funding risk — As a development-stage company with no revenue, it may require additional capital to fund operations, and the filing does not indicate a cash runway.
• Key person risk — The company's success depends on executives like CEO Robert Dempsey and the scientific leadership, whose loss could impair operations.

Outlook

Management has not provided forward-looking statements in the provided excerpts. The outlook is inferred to involve continued R&D on its pain candidates, with potential milestones such as clinical trial results or regulatory interactions. The company may seek additional financing to support its programs. No specific timeline or guidance is available in the filing excerpts.